E Tanaka, A Ishikawa, S Kobayashi, H Yasuhara, S Misawa, Y Kuroiwa
Index: Comp. Biochem. Physiol. C, Comp. Pharmacol. Toxicol. 104(2) , 205-7, (1993)
Full Text: HTML
1. Trimethadione (TMO) has the properties required of probe drugs for the evaluation of hepatic oxidizing capacity in vivo. 2. TMO is demethylated to dimethadione (DMO), its only metabolite, in the liver after oral administration. 3. In rats with various types of hepatic intoxicated-, induced- and partially hepatectomized-rats, the serum DMO/TMO ratios, which were measured on blood samples obtained by a single collection 2 hr after oral administration of TMO, correlated well with the degree of hepatic damage or induction. 4. This finding suggests that TMO may be used as a probe drug in the rapid determination of the functional reserve mass of the liver as well as the hepatic oxidizing capacity.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
Trimethadione
CAS:127-48-0 |
C6H9NO3 |
[Fetal trimethadione syndrome].
[Ryōikibetsu shōkōgun shirīzu (33) , 704, (2001)] |
[Fetal trimethadione effects].
[Ryōikibetsu shōkōgun shirīzu (30 Pt 5) , 94-5, (2000)] |
Trimethadione as a probe drug to estimate hepatic oxidizing ...
1996-11-01 [Comp. Biochem. Physiol. C, Pharmacol. Toxicol. Endocrinol. 115(3) , 211-6, (1996)] |
Zebrafish (Danio rerio) embryos as a model for testing prote...
2011-03-15 [Toxicology 281(1-3) , 25-36, (2011)] |
The antihyperalgesic effects of the T-type calcium channel b...
2005-10-03 [Eur. J. Pharmacol. 521(1-3) , 79-85, (2005)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved